Shyamala Maheswaran, PhD
Associate Professor of Surgery
Harvard Medical School
Assistant Molecular Biologist
Center for Cancer Research
Program AffiliationsCenter for Cancer Research
Explore the Maheswaran Lab
Metastasis, the leading cause of cancer-related deaths, is governed by multiple steps, which are not well understood. Using cell culture and mouse models, as well as patient-derived tumor tissues and tumor cells circulating in the blood (Circulating Tumor Cells/CTCs), the Maheswaran laboratory has uncovered novel tumor cell characteristics that promote metastasis in breast cancer patients. Our findings show that cancer cells exist in multiple cellular states, each state exhibiting different characteristics. As such, each breast cancer patient harbors a mixture of tumor cells with different functional properties. We intend to define the functional and molecular properties of different subclasses of tumor cells and their contribution to metastasis, tumor evolution and drug sensitivity using appropriate experimental models and patientderived samples. These findings will provide insight into the contribution of heterogeneous cancer cell populations to metastasis and their significance as biomarkers and therapeutic targets.
Mechanisms of Breast Cancer Metastasis
The research in my laboratory is focused on defining the molecular mechanisms that drive breast cancer progression and metastasis. Cancer, initially confined to the primary site, eventually spreads to distal sites, including lung, liver, bone and brain, by invading into the bloodstream. Upon reaching these distal sites, the tumor cells continue to grow and evolve well after removal of the primary tumor resulting in overt metastasis and disease recurrence, the leading causes of cancer-related deaths. Using cell culture and mouse models, patient derived tissues, and circulating tumor cells (CTCs) enriched from the blood of women with breast cancer, we characterize the contribution of oncogenic-and tumor-microenvironmentderived signals to cellular states including: epithelial to mesenchymal plasticity, senescence, and how these aspects of tumor heterogeneity influence cancer progression and therapeutic responses.
Metastasis through the Prisim of Circulating Tumor Cells
I am also collaborating with Drs. Daniel Haber and Mehmet Toner to define cancer biology across several tumor types including breast, prostate, liver, and lung cancers as well as melanoma using CTCs isolated from the blood of cancer patients. CTCs represent an extremely rare population of cells in the blood and their isolation presents a tremendous technical challenge. The CTC-iChip developed in Dr. Toner’s laboratory enables enrichment of live CTCs through selective removal of blood components; red and white blood cells as well as platelets. Characterizing CTCs has far-reaching implications for both clinical care and defining cancer biology. They enable real time monitoring of tumor cells during disease progression and therapeutic responses, and could possibly be used for early detection of disease. Viable CTCs cultured from patients provide tremendous insight into the molecular heterogeneity and cellular plasticity of tumors that govern differential biological characteristics and responses to therapy. Characterization of CTCs ties in well with the overall goal of the lab to study cancer metastasis.
Tajima K, Matsuda S, Yae T, Drapkin B, Morris R, Boukhali M, Niederhoffer K, Comaills V, Dubash T, Nieman L, Guo H, Magnus NKC, Dyson N, Shioda T, Haas W, Haber DA, Maheswaran S. SETD1A protects from senescence through regulation of the mitotic gene expression program. Nature Comm. 2019 Jun 28;10(1):2854.
Kwan TT, Bardia A, Spring LM, Giobbie-Hurder A, Kalinich M, Dubash T, Sundaresan T, Hong X, LiCausi JA, Ho U, Silva EJ, Wittner BS, Sequist LV, Kapur R, Miyamoto DT, Toner M, Haber DA, Maheswaran S. A digital RNA signature of Circulating Tumor Cells predicting early therapeutic response in localized and metastatic breast cancer. Cancer Discov. 2018 Aug 13
Comaills V, Kabeche L, Morris R, Buisson R, Yu M, Madden MW, LiCausi JA, Boukhali M, Tajima K, Pan S, Aceto N, Sil S, Zheng Y, Sundaresan T, Yae T, Jordan NV, Miyamoto DT, Ting DT, Ramaswamy S, Haas W, Zou L, Haber DA, Maheswaran S. Genomic Instability Induced by Persistent Proliferation of Cells Undergoing Epithelial-to- Mesenchymal Transition. Cell Reports 2016 Dec 6;17(10):2632-2647.
Tajima K, Yae T, Javaid S, Tam O, Comaills V, Morris R, Wittner BS, Liu M, Engstrom A, Takahashi F, Black JC, Ramaswamy S, Shioda T, Hammell M, Haber DA, Whetstine JR, Maheswaran S. SETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes. Nature Comm 2015 6:8257
Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, Brannigan BW, Kapur R, Stott SL, Shioda T, Ramaswamy S, Ting DT, Lin CP, Toner M, Haber DA*, Maheswaran S*. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 158(5):1110-22, 2014.
Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist MV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S. Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition. Science. 339(6119): 580-584, 2013.
Confocal images of cells stained with tubulin (green) and DAPI (magenta) show that SETD1A-KD cells escaping senescence harbor chromosome segregation defects visualized as micronuclei (circled). The scale bar represents 50 μm.
Shyamala Maheswaran, PhDPrincipal Investigator
- Risa Burr, PhD
- Brian Chirn
- Christina Costantino, MD
- Valentine Comaills, PhD
- Taronish Dubash, PhD
- Richard Ebright**
- Hongshan Guo, PhD
- Xin Hong, PhD
- Elad Horwitz, PhD
- Maria Kessler**
- Laura Libby
- Douglas Micalizzi, MD
- Stefanie Morgan, PhD*
- Benjamin Nicholson
- Britanny Reeves
- Joanna Vuille**
- Benjamin Wesley
- Devon Wiley
- Ben Wittner, PhD
** Graduate students